Life Science

Through our Life Sciences Advisory Board (LSAB), healthcare equity research analysts and investment bankers, NOBLE Life Science Partners combines industry and scientific knowledge to provide our clients with value-added research, advisory and investment and merchant banking services.


Noble Life Science Partners combines scientific knowledge and industry experience with capital markets expertise to accelerate the growth and profitability of undervalued emerging growth companies in biotechnology, specialty pharmaceuticals and medical technology.

Healthcare Verticals

Our analysts are further enriched by knowledge provided by our proprietary Life Sciences Advisory Board (LSAB) and Key Opinion Leader (KOL) relationships.

NOBLE Life Science Partners research covers leading Healthcare Verticals such as:

  • Biologics
  • Cardiovascular Disease
  • Cell Therapy
  • Diagnostics
  • Infectious Disease (HBV, HCV, HIV)
  • Stem Cells
  • Female Health
  • Pediatric Health
  • Oncology
  • Metabolic Disease
  • Neurology
  • Regenerative Medicine
  • Immunology, Inflammatory & Autoimmune Diseases
  • Vaccines

Advisory Board (SAB)

The Scientific Advisory Board (SAB) was formed for the overall objective of being instrumental and impactful in the growth and expansion of THE NOBLE LSP PLATFORM through highly focused, in-depth, and substantive advice with regards to new discoveries, technologies, products, services, new developments/trends in the Medical/Biotechnology/Pharmaceutical Industry worldwide.


Through fundamental equity research, non-deal roadshows, our equity conferences and daily dialogue with institutional investors, NOBLE increases the visibility of our corporate clients allowing for efficient and timely transactional access to the capital markets.

NOBLE Life Science Partners Transactions